Curis, Inc. is a drug discovery and development company that is committed to leveraging signaling pathway drug technologies in seeking to develop next generation network-targeted cancer therapies. The Company conducts its research and development programs both internally and through strategic collaborations. Its advanced program is Hedgehog pathway inhibitor program under collaboration with Genentech, Inc., a wholly owned member of the Roche Group. The lead drug candidate being developed under this program is Erivedge, a orally-administered small molecule Hedgehog pathway inhibitor, which is also known as vismodegib, GDC-0449 and RG3616. In October 2011, the Company completed a Phase Ib expansion trial to test CUDC-101. The Company�s other development candidate under collaboration is Debio 0932 (formerly CUDC-305).